Skip to content

Study · In vitro (cells) · 2010

4 results

Expression of activity-dependent neuroprotective protein in the immune system: possible functions and relevance to multiple sclerosis.

Braitch M, Kawabe K, Nyirenda M, Gilles LJ, Robins RA, Gran B, Murphy S, Showe L, Constantinescu CS

Neuroimmunomodulation17 Nov 2009Cited by 34 (Europe PMC)

PMID19923857 (opens in a new tab)PMCIDPMC3701887 (opens in a new tab)DOI10.1159/000258695 (opens in a new tab)PepBankPUB-19923857
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In human PBMCs, NAP decreased CD69 expression.

    In plain wordsIn cells, NAP reduced CD69 expression in human immune cells.

    Peptide
    Davunetide
    Outcome
    DecreaseCD69 expression
    Study

    humann: not reported in source

    Peripheral blood mononuclear cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NAP peptide decreased the expression of CD69, CD154 and IFN-gamma in PBMC and caused suppressed anti-CD3-/anti-CD28-stimulated PBMC proliferation.
    1 context sentence
    Summary · context
    Effects of NAP on immune cell proliferation was assessed by tritiated thymidine incorporation.
  2. 02LabIn vitro (cells)Mechanism

    In human PBMCs, NAP decreased CD154 expression.

    In plain wordsIn cells, NAP reduced CD154 expression in human immune cells.

    Peptide
    Davunetide
    Outcome
    DecreaseCD154 expression
    Study

    humann: not reported in source

    Peripheral blood mononuclear cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NAP peptide decreased the expression of CD69, CD154 and IFN-gamma in PBMC and caused suppressed anti-CD3-/anti-CD28-stimulated PBMC proliferation.
    1 context sentence
    Summary · context
    Effects of NAP on immune cell proliferation was assessed by tritiated thymidine incorporation.
  3. 03LabIn vitro (cells)Mechanism

    In human PBMCs, NAP decreased IFN-gamma expression.

    In plain wordsIn cells, NAP reduced IFN-gamma expression in human immune cells.

    Peptide
    Davunetide
    Outcome
    DecreaseIFN-gamma expression
    Study

    humann: not reported in source

    Peripheral blood mononuclear cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NAP peptide decreased the expression of CD69, CD154 and IFN-gamma in PBMC and caused suppressed anti-CD3-/anti-CD28-stimulated PBMC proliferation.
    1 context sentence
    Summary · context
    Effects of NAP on immune cell proliferation was assessed by tritiated thymidine incorporation.
  4. 04LabIn vitro (cells)Activity measurement

    In human PBMCs, NAP suppressed anti-CD3-/anti-CD28-stimulated proliferation.

    In plain wordsIn cells, NAP suppressed stimulated human immune cell multiplication.

    Peptide
    Davunetide
    Outcome
    DecreaseStimulated PBMC proliferation
    Study

    humann: not reported in source

    Peripheral blood mononuclear cells
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NAP peptide decreased the expression of CD69, CD154 and IFN-gamma in PBMC and caused suppressed anti-CD3-/anti-CD28-stimulated PBMC proliferation.
    1 context sentence
    Summary · context
    Effects of NAP on immune cell proliferation was assessed by tritiated thymidine incorporation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.